Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
HOLX Stock Forecast 2025-2026
$74.97
Current Price
$16.71B
Market Cap
Buy 3
Hold 15
Sell 0
Wall St Analyst Ratings
Distance to HOLX Price Targets
+6.7%
To High Target of $80.00
+2.7%
To Median Target of $77.00
-6.6%
To Low Target of $70.00
HOLX Price Momentum
0.0%
1 Week Change
+1.1%
1 Month Change
-0.5%
1 Year Change
+4.0%
Year-to-Date Change
-6.6%
From 52W High of $80.31
+44.5%
From 52W Low of $51.90
📊 TOP ANALYST CALLS
Did HOLX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Hologic is one of their latest high-conviction picks.
Latest HOLX Stock Price Targets & Analyst Predictions
Based on our analysis of 27 Wall Street analysts, HOLX has a neutral consensus with a median price target of $77.00 (ranging from $70.00 to $80.00). The overall analyst rating is Buy (6.7/10). Currently trading at $74.97, the median forecast implies a 2.7% upside. This outlook is supported by 3 Buy, 15 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Patrick Donnelly at Citigroup, projecting a 6.7% upside. Conversely, the most conservative target is provided by Elizabeth Garcia at UBS, suggesting a 6.6% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
HOLX Analyst Ratings
3
Buy
15
Hold
0
Sell
HOLX Price Target Range
Low
$70.00
Average
$77.00
High
$80.00
Current: $74.97
Latest HOLX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for HOLX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 11, 2025 | Morgan Stanley | Tejas Savant | Equal-Weight | Maintains | $76.00 |
| Oct 23, 2025 | Mizuho | Anthony Petrone | Neutral | Downgrade | $78.00 |
| Oct 22, 2025 | Raymond James | Andrew Cooper | Market Perform | Downgrade | $N/A |
| Oct 22, 2025 | Stephens & Co. | Mason Carrico | Equal-Weight | Downgrade | $76.00 |
| Oct 22, 2025 | JP Morgan | Casey Woodring | Neutral | Downgrade | $78.00 |
| Oct 21, 2025 | Needham | Mike Matson | Hold | Reiterates | $N/A |
| Oct 21, 2025 | BTIG | Ryan Zimmerman | Neutral | Reiterates | $N/A |
| Oct 21, 2025 | Leerink Partners | Puneet Souda | Market Perform | Maintains | $78.00 |
| Oct 7, 2025 | Evercore ISI Group | Vijay Kumar | Outperform | Upgrade | $78.00 |
| Sep 19, 2025 | Argus Research | David Toung | Buy | Maintains | $90.00 |
| Sep 18, 2025 | Stephens & Co. | Mason Carrico | Overweight | Reiterates | $78.00 |
| Aug 6, 2025 | RBC Capital | Conor McNamara | Outperform | Upgrade | $87.00 |
| Jul 31, 2025 | UBS | Elizabeth Garcia | Neutral | Maintains | $70.00 |
| Jul 31, 2025 | Morgan Stanley | Tejas Savant | Equal-Weight | Maintains | $69.00 |
| Jul 16, 2025 | Mizuho | Anthony Petrone | Outperform | Maintains | $70.00 |
| Jul 9, 2025 | Citigroup | Patrick Donnelly | Buy | Upgrade | $80.00 |
| Jul 8, 2025 | Evercore ISI Group | Vijay Kumar | In-Line | Maintains | $68.00 |
| May 28, 2025 | Needham | Mike Matson | Hold | Reiterates | $N/A |
| May 13, 2025 | Stephens & Co. | Mason Carrico | Overweight | Maintains | $70.00 |
| May 5, 2025 | Morgan Stanley | Tejas Savant | Equal-Weight | Maintains | $65.00 |
Hologic Inc. (HOLX) Competitors
The following stocks are similar to Hologic based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Hologic Inc. (HOLX) Financial Data
Hologic Inc. has a market capitalization of $16.71B with a P/E ratio of 30.1x. The company generates $4.10B in trailing twelve-month revenue with a 13.8% profit margin.
Revenue growth is +6.2% quarter-over-quarter, while maintaining an operating margin of +32.7% and return on equity of +11.1%.
Valuation Metrics
Market Cap
$16.71B
Enterprise Value
$17.13B
P/E Ratio
30.1x
PEG Ratio
2.9x
Price/Sales
4.1x
Growth & Margins
Revenue Growth (YoY)
+6.2%
Gross Margin
+55.6%
Operating Margin
+32.7%
Net Margin
+13.8%
EPS Growth
+4.8%
Financial Health
Cash/Price Ratio
+13.2%
Current Ratio
3.8x
Debt/Equity
52.0x
ROE
+11.1%
ROA
+7.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Hologic Inc. (HOLX) Business Model
About Hologic Inc.
What They Do
Develops medical technology for women's health.
Business Model
Hologic Inc. generates revenue by developing, manufacturing, and supplying a range of diagnostic products, medical imaging systems, and surgical products aimed at improving women's health. The company operates in key sectors such as breast health, diagnostics, gynecological surgical solutions, and skeletal health, leveraging innovative technologies like 3D mammography to enhance disease prevention and treatment.
Additional Information
With its headquarters in Marlborough, Massachusetts, Hologic has established a significant presence in the global healthcare sector, catering to various healthcare settings, including hospitals, clinics, laboratories, and research facilities. Its commitment to innovation and quality positions it as a leader in women's health diagnostics.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
7,070
CEO
Mr. Stephen P. MacMillan
Country
United States
IPO Year
1990
Website
www.hologic.comHologic Inc. (HOLX) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Hologic's BCI Test Shows Growing Impact in Endocrine Therapy Decisions
HOLX's BCI test gains traction as new SABCS studies are set to highlight its growing role in guiding extended endocrine therapy decisions.
Dec 04, 2025
By Moumi Mondal
Analyst Blog
Cooper Companies to Post Q4 Earnings: What's in Store for the Stock?
COO is set to post Q4 earnings as MyDAY momentum offsets Clariti and APAC softness, with revenues and earnings expected to rise.
Dec 03, 2025
By Zacks Equity Research
Analyst Blog
Why Is Hologic (HOLX) Up 1% Since Last Earnings Report?
Hologic (HOLX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Dec 03, 2025
By Zacks Equity Research
Realtime BLOG
Latest News
Quick Summary
Hologic (HOLX) reported earnings 30 days ago; investors should monitor upcoming developments and market reactions for future stock performance.
Why It Matters
Upcoming developments for Hologic could impact stock performance and investor sentiment, particularly if earnings reveal growth potential or operational challenges.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Hologic ($HOLX) will present new data at the 2025 SABCS showcasing the potential expanded utility of its Breast Cancer Index Test.
Why It Matters
The announcement of expanded utility for the Breast Cancer Index Test could enhance Hologic's market position and revenue potential, influencing investor sentiment and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Hologic (HOLX) is currently a focus for Zacks.com users, indicating heightened interest and potential market activity for the stock.
Why It Matters
Heightened interest in Hologic (HOLX) indicates potential volatility and investment opportunities, signaling changes in market perception or upcoming developments that could impact stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
HOLX will present new real-world data at RSNA 2025, demonstrating that its AI-driven breast imaging tools enhance workflow while maintaining detection accuracy.
Why It Matters
HOLX's upcoming presentation of AI-driven breast imaging data at RSNA 2025 could enhance its market position, potentially leading to increased sales and investor confidence.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Zacks Premium offers Style Scores to help investors identify strong stocks across value, growth, and momentum categories.
Why It Matters
The Zacks Style Scores can enhance stock selection across investment strategies, potentially leading to better returns and informed decision-making for investors.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
DGX shows strong year-to-date gains and growth in advanced diagnostics and acquisitions, positioning it favorably against competitor HOLX in the testing market.
Why It Matters
DGX's strong performance and growth in advanced diagnostics position it favorably against HOLX, indicating potential for continued investment returns and market leadership.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About HOLX Stock
What is Hologic Inc.'s (HOLX) stock forecast for 2026?
Based on our analysis of 27 Wall Street analysts, Hologic Inc. (HOLX) has a median price target of $77.00. The highest price target is $80.00 and the lowest is $70.00.
Is HOLX stock a good investment in 2026?
According to current analyst ratings, HOLX has 3 Buy ratings, 15 Hold ratings, and 0 Sell ratings. The stock is currently trading at $74.97. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for HOLX stock?
Wall Street analysts predict HOLX stock could reach $77.00 in the next 12 months. This represents a 2.7% increase from the current price of $74.97. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Hologic Inc.'s business model?
Hologic Inc. generates revenue by developing, manufacturing, and supplying a range of diagnostic products, medical imaging systems, and surgical products aimed at improving women's health. The company operates in key sectors such as breast health, diagnostics, gynecological surgical solutions, and skeletal health, leveraging innovative technologies like 3D mammography to enhance disease prevention and treatment.
What is the highest forecasted price for HOLX Hologic Inc.?
The highest price target for HOLX is $80.00 from Patrick Donnelly at Citigroup, which represents a 6.7% increase from the current price of $74.97.
What is the lowest forecasted price for HOLX Hologic Inc.?
The lowest price target for HOLX is $70.00 from Elizabeth Garcia at UBS, which represents a -6.6% decrease from the current price of $74.97.
What is the overall HOLX consensus from analysts for Hologic Inc.?
The overall analyst consensus for HOLX is neutral. Out of 27 Wall Street analysts, 3 rate it as Buy, 15 as Hold, and 0 as Sell, with a median price target of $77.00.
How accurate are HOLX stock price projections?
Stock price projections, including those for Hologic Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 6, 2025 8:13 AM UTC